vVARDIS Hits Unicorn Status with Drill-Free Dental Tech Investment

ZUG, Switzerland – April 27, 2026 – Swiss dental medtech firm vVARDIS Holding AG has officially joined the exclusive club of European unicorns, announcing a strategic minority investment from Apollo-managed funds that pushes its valuation beyond the billion-dollar threshold. The capital infusion is set to accelerate the global expansion of its groundbreaking Curodont™ technology, a non-invasive treatment designed to regenerate early-stage tooth decay and potentially make the dentist's drill a thing of the past for millions.

The investment marks a significant milestone for vVARDIS, founded and led by co-CEOs and sisters Drs. Haley and Goly Abivardi, who will retain a substantial majority shareholding in the company. It validates a disruptive approach to one of the world's most common diseases and signals strong investor confidence in the future of generative dentistry.

A Billion-Dollar Bet on a Painless Future

The backing from a global alternative asset manager like Apollo, which managed approximately $938 billion as of late 2025, is a powerful endorsement. For vVARDIS, it provides not just capital but also a strategic partnership to navigate its next phase of commercial growth across key markets in the United States and Europe. For Apollo, the investment aligns with a strategy of backing differentiated, high-growth businesses that are pioneering new categories.

“vVARDIS has built a differentiated business, with Drs. Haley and Goly Abivardi pioneering a new category in dental care backed by peer-reviewed clinical studies,” said Jeremy Honeth, Partner at Apollo. Along with Managing Director Andrea Vanni, he noted that the investment is aimed at “bringing this restorative therapy to more practices and patients worldwide.”

Achieving unicorn status is a notable feat in the European medtech landscape. The sector includes thousands of companies, yet only a handful have reached a billion-dollar private valuation. The move underscores a broader trend where private equity is increasingly identifying and fueling innovative healthcare technologies that promise not only significant financial returns but also profound societal impact. The investment in vVARDIS highlights a focus on companies with proven clinical results and a clear path to disrupting established, often antiquated, standards of care.

Redefining Dentistry Beyond the Drill

At the heart of vVARDIS's valuation is its Curodont™ technology, a product born from over 25 years of scientific research. The treatment is centered on a proprietary P11-4 peptide that, when applied to an early-stage cavity, diffuses into the porous lesion. There, it self-assembles into a biomimetic scaffold that attracts calcium and phosphate ions from saliva, effectively guiding the natural regeneration of crystalline enamel structure throughout the affected tooth area.

This process stands in stark contrast to the traditional “drill and fill” approach, which involves the removal of tooth structure and its replacement with a synthetic material. It also offers a significant aesthetic advantage over other non-invasive alternatives like Silver Diamine Fluoride (SDF), which can arrest decay but often leaves a permanent black stain on the tooth.

“Our mission is to bring a medical, science driven approach to dentistry,” said Dr. Goly Abivardi, co-CEO and co-founder of vVARDIS. “Using peptide-containing formulations, our non-invasive technology is an innovative treatment designed to treat tooth decay without drilling and without polymer materials.”

The clinical evidence supporting Curodont™ is extensive, with over 250 scientific publications, including meta-analyses and long-term peer-reviewed studies. A JADA-published meta-analysis found the treatment significantly increased caries arrest and reduced lesion size. Other long-term clinical data has demonstrated a success rate exceeding 90% in arresting and even regressing early caries, a figure far superior to traditional fluoride varnish treatments alone.

Rapid Adoption and the Patient Experience Revolution

The technology's rapid market penetration speaks to a significant unmet need. Since launching in the U.S. just over two years ago, Curodont™ Repair Fluoride Plus has been used to treat an estimated 3 million teeth and is now utilized in nearly 20 percent of general dental practices nationwide, making it one of the fastest-growing products in the U.S. dental market.

This swift adoption is driven by benefits for both clinicians and patients. For dentists and hygienists, it provides a quick, easy-to-use tool—applied in under 10 minutes—to actively treat early decay rather than passively “watching and waiting.” For patients, the appeal is obvious: a painless, needle-free, and silent alternative to the anxiety-inducing dental drill. This has led to high patient acceptance, with many willing to pay out-of-pocket for the procedure, a crucial factor as insurance reimbursement for this novel treatment remains inconsistent.

“Curodont™ fills a longstanding gap in dentistry: when prevention fails, dentists now have a quick, easy-to-use non-invasive treatment free of drilling and needles,” explained Dr. Haley Abivardi, co-CEO and co-founder.

Tackling a Global Health Crisis

The implications of this technology extend far beyond the dental chair. Tooth decay is the world’s most prevalent non-communicable disease, affecting nearly 90 percent of adults in the United States alone. Untreated oral disease is not an isolated issue; it is closely linked to overall health and can contribute to serious chronic conditions, with studies suggesting a 26 percent increased risk of all-cause mortality.

By providing a non-invasive option, Curodont™ aligns directly with modern public health goals and World Health Organization (WHO) guidelines that emphasize early intervention and minimally invasive care. It has the potential to lower barriers to treatment, particularly for the large portion of the population that experiences dental anxiety, thereby improving access and promoting better long-term health outcomes.

With an addressable market estimated at over $30 billion in the U.S. alone, the opportunity is immense. The strategic investment from Apollo will not only strengthen vVARDIS’s commercial foundation in its current markets but also empower its mission to scale this sustainable technology globally, promising a future where managing tooth decay is a far less invasive and far more accessible endeavor.